Occidental Asset Management LLC Boosts Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Occidental Asset Management LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 38,616 shares of the biopharmaceutical company's stock after purchasing an additional 3,980 shares during the quarter. Occidental Asset Management LLC's holdings in Gilead Sciences were worth $3,567,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Avior Wealth Management LLC grew its holdings in Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock valued at $782,000 after buying an additional 108 shares in the last quarter. Concord Asset Management LLC VA grew its stake in Gilead Sciences by 3.8% during the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company's stock valued at $256,000 after acquiring an additional 111 shares in the last quarter. TFB Advisors LLC increased its holdings in Gilead Sciences by 1.2% during the 3rd quarter. TFB Advisors LLC now owns 9,397 shares of the biopharmaceutical company's stock worth $788,000 after acquiring an additional 116 shares during the period. Sumitomo Life Insurance Co. lifted its stake in Gilead Sciences by 0.7% in the 3rd quarter. Sumitomo Life Insurance Co. now owns 17,822 shares of the biopharmaceutical company's stock worth $1,494,000 after purchasing an additional 117 shares in the last quarter. Finally, FDx Advisors Inc. boosted its holdings in Gilead Sciences by 2.2% in the 3rd quarter. FDx Advisors Inc. now owns 5,365 shares of the biopharmaceutical company's stock valued at $450,000 after purchasing an additional 117 shares during the period. Institutional investors own 83.67% of the company's stock.

Analysts Set New Price Targets

GILD has been the topic of several research analyst reports. Bank of America reaffirmed a "buy" rating and issued a $109.00 price target on shares of Gilead Sciences in a report on Tuesday, December 10th. Robert W. Baird lifted their price target on Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a research report on Thursday, November 7th. Piper Sandler upped their price objective on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Maxim Group lowered shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Finally, BMO Capital Markets increased their price target on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Eleven investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have issued a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $97.96.

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 456,234 shares of company stock valued at $42,130,461. Insiders own 0.29% of the company's stock.

Gilead Sciences Stock Performance

GILD traded up $0.60 during mid-day trading on Friday, reaching $92.25. 3,884,115 shares of the company traded hands, compared to its average volume of 6,455,747. The stock has a market capitalization of $114.97 billion, a P/E ratio of 1,024.77, a P/E/G ratio of 1.27 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company's fifty day moving average price is $91.97 and its 200-day moving average price is $83.76.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating analysts' consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. Gilead Sciences's revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.29 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.34%. Gilead Sciences's dividend payout ratio (DPR) is 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.